Page last updated: 2024-08-21

quinazolines and Hemorrhagic Thrombocythemia

quinazolines has been researched along with Hemorrhagic Thrombocythemia in 163 studies

Research

Studies (163)

Timeframe	Studies, this research(%)	All Research%
pre-1990	1 (0.61)	18.7374
1990's	19 (11.66)	18.2507
2000's	68 (41.72)	29.6817
2010's	60 (36.81)	24.3611
2020's	15 (9.20)	2.80

Authors

Authors	Studies
Ebata, K; Nakamura, H; Narahira, A; Nohara, T; Sugai, T; Ujiie, H; Yamaguchi, Y	1
Fleischman, A; Gotlib, J; Heaney, M; Hoffman, R; Kremyanskaya, M; Kuykendall, A; Mascarenhas, J; Mesa, R; O'Connell, C; Podoltsev, N; Rippel, N; Shammo, JM; Tremblay, D; Yacoub, A; Zubizarreta, N	1
Gill, H; Hou, HA; Jin, J; Komatsu, N; Lee, SE; Mesa, RA; Qin, A; Sato, T; Shih, W; Urbanski, R; Verstovsek, S; Zagrijtschuk, O; Zimmerman, C	1
Alvarez-Larrán, A; Ferrer-Marín, F; Santaliestra, M	1
Bieniaszewska, M; Dutka, M; Leszczyńska, A; Sobieralski, P	1
Arimura, A; Fujii, K; Hashiguchi, T; Hayashida, M; Higashi, Y; Kanekura, T	1
Fujita, S; Hashimoto, A; Hashimoto, Y; Hotta, M; Ishii, K; Ito, T; Kondo, T; Konishi, A; Nakanishi, T; Nakaya, A; Nomura, S; Omura, H; Satake, A; Shinzato, I; Tanaka, T; Tanaka, Y; Yoshimura, H	2
Anaclerico, B; Andriani, A; Baldacci, E; Breccia, M; Cedrone, M; Cimino, G; Di Veroli, A; Latagliata, R; Mazzucconi, MG; Montanaro, M; Montefusco, E; Paoloni, F; Porrini, R; Rago, A; Santoro, C; Scaramucci, L; Spadea, A; Spirito, F; Villivà, N	1
Demeter, J; Dombi, P; Egyed, M; Ercsei, I; Gasztonyi, Z; Gy Korom, V; Herczeg, J; Homor, L; Illes, A; Karadi, E; Kellner, A; Simon, Z; Szerafin, L; Udvardy, M	1
Alvarez-Larrán, A; Andrade-Campos, M; Angona, A; Bellosillo, B; Caballero, G; Carreño-Tarragona, G; Cuevas, B; Ferrer-Marín, F; Fox, L; García-Gutiérrez, V; García-Hernández, C; Guerrero, L; Hernández-Boluda, JC; Isabel Mata-Vázquez, M; Magro, E; Manuel Alonso-Domínguez, J; María Guerra, J; María Raya, J; Moretó, A; Murillo, I; Palomino, A; Pastor-Galán, I; Pérez-Encinas, M; Soledad Noya, M; Teresa Gómez-Casares, M	1
Achenbach, H; Egyed, M; Gercheva, L; Gotic, M; Kvasnicka, HM; Warzocha, K; Wu, J	1
Fukushima, K; Gatate, Y; Muramatsu, T; Naganuma, K; Nakano, S; Ohta, A; Shimizu, Y; Sujino, Y; Tanaka, R; Todo, M; Watanabe, A	1
Jaźwiec, B; Kuliszkiewicz-Janus, M; Kwiatkowski, J; Małecki, R; Rymer, W	1
Cario, H; Duffert, CM; Knöfler, R; Kulozik, AE; Stockklausner, C; Streif, W	1
Krečak, I; Lucijanić, M	1
Ito, T; Kajiguchi, T; Kamoshita, S; Kimura, T; Yagi, M	1
Baek, S; Choi, SY; Lee, H; Na, J	1
Alimena, G; Anaclerico, B; Andriani, A; Avvisati, G; Baldacci, E; Breccia, M; Buccisano, F; Cedrone, M; Cimino, G; De Gregoris, C; De Muro, M; Di Veroli, A; Latagliata, R; Leonetti Crescenzi, S; Mazzucconi, MG; Montanaro, M; Montefusco, E; Porrini, R; Rago, A; Santoro, C; Spadea, A; Sperduti, I; Spirito, F; Villivà, N	1
Kanai, A; Matsuda, K; Morokawa, H; Nakazawa, Y; Shimazaki, E	1
Berveiller, P; Cornet, N; Mir, O; Vialard, F	1
Greenspan, A; Lu, M; Rodriguez-Ziccardi, M; Rubio, M	1
Atkinson, E; Bakri, M; Hayat, A; Langabeer, SE	1
Begna, KH; Christopher Hook, C; Elliott, MA; Gangat, N; Hanson, CA; Ketterling, RP; Pardanani, A; Patnaik, MM; Szuber, N; Tefferi, A; Vallapureddy, RR; Wolanskyj, AP	1
Achenbach, H; Besses, C; Birgegård, G; Folkvaljon, F; Garmo, H; Griesshammer, M; Gugliotta, L; Harrison, CN; Holmberg, L; Kiladjian, JJ; Wu, J	1
Kuznetsova, PI; Melikyan, AL; Raskurazhev, AA; Subortseva, IN; Tanashyan, MM	1
Fukuda, Y; Hamano, Y; Iizuka, H; Inano, T; Izumi, H; Nakamura, N; Noguchi, M; Okubo, M; Sakajiri, S; Sawada, T; Sekiguchi, Y; Sugimoto, K; Takizawa, H; Tomita, S; Wakabayashi, M	1
Alvarez-Larrán, A; Besses, C; Cervantes, F	1
Haznedaroglu, IC	1
Cervinek, L; Dulíček, P; Kissová, J; Ovesná, P; Pavlík, T; Penka, M; Pospíšilová, D; Schwarz, J	1
Fu, R; Yang, R; Zhang, L	1
Keddad, K; Kiladjian, JJ; Rey, J; Smith, J; Viallard, JF; Wilde, P	1
Cortelazzo, S; Corvetta, D; Gastl, G; Mazzoleni, G; Piccin, A; Pusceddu, I; Rovigatti, U; Steurer, M; Svaldi, M	1
Ahn, IE; Natelson, E; Rice, L	1
Chaudhary, R; Nityanand, S; Singh, A	1
Abhyankar, B; Besses, C; Birgegård, G; Coll, R; Griesshammer, M; Gugliotta, L; Harrison, C; Kiladjian, JJ; Smith, J	2
Newberry, KJ; Sever, M; Verstovsek, S	1
De Raeve, H; Gadisseur, A; Michiels, JJ; Pich, A	1
Achenbach, H; Kanakura, Y; Miyakawa, Y; Okamoto, S; Smith, J; Wilde, P	1
Miyamoto, T; Yoshimoto, G	1
Espasandin, YR; Glembotsky, AC; Goette, NP; Grodzielski, M; Heller, PG; Lev, PR; Marta, RF; Molinas, FC	1
Double, G; Harrison, C	1
Bang, SM; Kim, JW; Kim, SH; Kim, YJ; Lee, JO; Lee, JS; Lee, KW; Lim, Y	1
Birtolo, C; Codeluppi, K; Cortelazzo, S; Fama, A; Gastl, G; Gugliotta, G; Gugliotta, L; Marcheselli, L; Piccin, A; Santoro, U; Steurer, M; Tieghi, A; Tortorella, G	1
Chai-Adisaksopha, C; Garcia, D; Samuelson, B	1
Achenbach, H; Cascavilla, N; D'Adda, M; De Stefano, V; Fjerza, R; Gaidano, G; Gobbi, M; Iurlo, A; Liberati, AM; Palandri, F; Pancrazzi, A; Pane, F; Smith, J; Specchia, G; Vannucchi, AM; Wilde, P	1
Alvarez, C; Ferrari, L; Glembotsky, AC; Goette, NP; Gutierrez, MI; Heller, PG; Korin, L; Lev, PR; Maldonado, AC; Marta, RF; Mela Osorio, MJ; Molinas, FC	1
Cao, X; Fu, J; Gao, D; Ge, X; Hou, M; Jiang, B; Jin, J; Li, J; Li, K; Qian, W; Su, L; Sun, A; Wang, S; Wang, Z; Xiao, Z; Yang, L; Yang, R; Zhang, W; Zhang, X; Zhao, Y	1
Burlando, M; Cattaneo, D; Cozzani, E; Gugliotta, L; Iurlo, A; Merlo, G; Parodi, A; Pierri, I	1
Tersak, JM; Wigton, JC	1
Iványi, JL; Marton, É; Plander, M; Szendrei, T	1
Besses, C; Burgaleta, C; Hernández-Boluda, JC; Hernández-Rivas, JM; Jiménez Velasco, A; Martínez Lopez, J; Pérez Encinas, M; Raya, JM; Vicente, V	1
Buxhofer-Ausch, V; Gastl, G; Gisslinger, B; Gisslinger, H; Ruckser, R; Schimetta, W; Schloegl, E; Sormann, S; Steurer, M	1
Bucelli, C; Cattaneo, D; Cortelezzi, A; Fabris, S; Iurlo, A; Orofino, N	1
Bertele', V; Garattini, S; Gerardi, C; Joppi, R	1
Kitanaka, A; Shimoda, K	1
Birgegård, G	3
Fujimura, K; Shimazu, Y	1
Demeter, J; Dombi, P; Egyed, M; Homor, L; Illés, Á; Karadi, E; Simon, Z; Udvardy, M	1
Corvetta, D; Di Pierro, AM; Eakins, E; Feistritzer, C; Gambato, R; Gastl, G; Gherlinzoni, F; Gottardi, M; Krampera, M; Langes, M; Marcheselli, L; Mazzoleni, G; Mega, A; Murphy, C; Pacquola, E; Perbellini, O; Piccin, A; Piva, E; Plebani, M; Pusceddu, I; Steurer, M; Tauber, M; Van Schilfgaarde, M; Veneri, D	1
Barbui, T; Finazzi, G	2
Anastasiadis, A; Bourikas, G; Christoforidou, A; Goutzouvelidis, A; Kaloutsi, V; Kotsianidis, I; Margaritis, D; Pantelidou, D; Spanoudakis, E; Tsatalas, C	1
Reilly, JT	2
Bareford, D; Buck, G; Campbell, PJ; Erber, WN; Green, AR; Harrison, CN; Wheatley, K; Wilkins, BS; Wright, P	1
Dai, Y; Hoffman, R; Ishii, T; Mascarenhas, J; Najfeld, V; Sozer, S; Wang, J; Wisch, N; Xu, M; Zhang, W; Zhao, ZJ	1
Besses, C; Burgaleta, C; Carbonell, F; Giralt, M; Hernández-Nieto, L; Navas, V; Ramírez, G; Vicente, V	1
Bello López, JL; Pérez Encinas, MM; Quinteiro García, C; Rabuñal Martinez, MJ; Sobas, MA	1
Beer, PA; Green, AR	1
Bodzásová, C; Brychtová, Y; Cerná, O; Doubek, M; Dulícek, P; Dusek, L; Hadacová, I; Hlusí, A; Hochová, I; Indrák, K; Jelínková, P; Jonásová, A; Kissová, J; Korístek, Z; Nováková, L; Pavlík, T; Penka, M; Pospísilová, D; Schutzová, M; Schwarz, J; Segethová, J; Voglová, J; Vozobulová, V; Walterová, L	1
Demulder, AC; Malarme, M; Mesquita, Mdo C; Noubouossie, D; Sol, EB	1
Schlag, R; Schmitz, S; Stauch, M	1
Buliková, A; Doubek, M; Dulícek, P; Hlusí, A; Kissová, J; Korístek, Z; Ovesná, P; Pavlík, T; Penka, M; Pospísilová, D; Schwarz, J	1
Griesshammer, M	2
Cacciola, E; Cacciola, R; Candoni, A; Ciancia, R; Codeluppi, K; Crugnola, M; Grossi, A; Gugliotta, L; Iurlo, A; Liberati, AM; Lunghi, M; Martinelli, V; Mazzucconi, MG; Palmieri, F; Pierri, I; Scalzulli, PR; Specchia, G; Tieghi, A; Tortorella, G; Usala, E; Vannucchi, AM; Vianelli, N	1
Besses, C; Martínez-Sellés, M	1
Finazzi, G	1
Dubiel, JS; Dudek, D; Dziewierz, A; Kleczyński, P; Olszanecka, A; Rakowski, T; Wiliński, J	1
Cebula-Obrzut, B; Chojnowski, K; Smolewski, P; Treliński, J	1
Dowson, A; Frewin, R	1
Alvarez-Larrán, A; Besses, C; Coll, R; Freitag, C; Martin, P; Purkayastha, J; Troy, S; Zeller, W	1
García-Sanchez, R; Plaza, S; Ramirez, G	1
Besses, C; Birgegård, G; Coll, R; Griesshammer, M; Gugliotta, L; Harrison, C; Kiladjian, JJ; Smith, J	1
Gisslinger, H; Gotic, M; Holowiecki, J; Kralovics, R; Kvasnicka, HM; Penka, M; Petrides, PE; Thiele, J	1
Alvarez-Larrán, A; Antelo, ML; Arellano-Rodrigo, E; Besses, C; Cervantes, F; Ferrer-Marín, F; Gómez, M; Hernández-Boluda, JC; Kerguelen, A; Márquez, JA; Pereira, A	1
Abhyankar, B; Hodgson, I; Kanakura, Y; Miyakawa, Y; Okamoto, S; Smith, J; Troy, S	1
Heller, P; Kornblihtt, LI; Molinas, FC; Vassallu, PS	1
Andersson, BS	1
Giles, FJ; Tsimberidou, AM	1
Barbui, T	2
Barbui, T; Finazzi, G; Rodeghiero, F; Ruggeri, M	1
Griesshammer, M; Langer, C	1
Castañón, M; Correa, G; Genoud, V; Heller, PG; Kordich, L; Kornblihtt, LI; Molinas, FC; Sarano, J; Vassallu, P	1
Schafer, AI	1
Putti, MC; Randi, ML	1
Campbell, PJ; Curtin, N; Green, AR; Vassiliou, GS	1
Petrides, PE	3
Brychtova, Y; Doubek, M; Doubek, R; Janku, P; Mayer, J	1
Fay, M; Murphy, PT; O'Donnell, R; Swords, R	1
Cacciola, E; Cacciola, RR; Francesco, ED; Giustolisi, R	1
Bernasconi, S; Bizzoni, L; Dragoni, F; Latagliata, R; Mandelli, F; Mazzucconi, MG; Redi, R; Santoro, C	1
Jurgens, DJ; Moreno-Aspitia, A; Tefferi, A	1
Heller, PG; Kornblihtt, LI; Lev, PR; Marta, RF; Molinas, FC; Pirola, CJ; Salim, JP	1
Kuliczkowski, K; Kuliszkiewicz-Janus, M; Mazur, G; Nosol, J; Podolak-Dawidziak, M; Potoczek, S; Wróbel, T	1
Bareford, D; Buck, G; Campbell, PJ; East, CL; Green, AR; Grigg, AP; Harrison, CN; Reilly, JT; Revell, P; van der Walt, JD; Wheatley, K; Wilkins, BS; Woodcock, BE	1
Dingli, D; Tefferi, A	1
Cocorullo, S; Heller, PG; Kornblihtt, LI; Lylyk, P; Miranda, C; Molinas, FC	1
Baughman, RP; Engel, PJ; Johnson, H; Richards, AI	1
Costello, R; O'Callaghan, T; Sébahoun, G	1
Cacciola, E; Cacciola, RR; Cipolla, A; Di Francesco, E; Giustolisi, R	1
Keating, GM; Wagstaff, AJ	1
Lawrence, DS; Spencer, EM	1
Gutknecht, D; Pachipala, K	1
Harrison, CN	1
Cabello, P; Cesar, JM; Ferro, T; Navarro, JL	1
Belada, D; Brychtová, Y; Bubeník, B; Cerná, O; Doubek, M; Dulícek, P; Dusek, L; Hadacová, I; Hlusí, A; Hochová, I; Kissová, J; Lhot'anová, T; Micaníková, M; Penka, M; Pytlík, R; Schutzová, M; Schwarz, J; Seghetová, J; Siroký, O; Szotkowski, T; Voglová, J; Volková, Z; Vozobulová, V; Vránová, M	1
Kvasnicka, HM; Schmitt-Graeff, A; Thiele, J	1
Gisslinger, H	1
Lee, LH; Wong, GC	1
Benesch, M; Dornbusch, HJ; Lackner, H; Moser, A; Schwinger, W; Sovinz, P; Urban, C	1
Chang, H; Cheong, JW; Choi, D; Jang, Y; Ko, YG; Pyo, JY; Shim, CY	1
Goette, NP; Marta, RF; Molinas, FC	1
Chao, TY; Lin, GM; Wang, WB	1
Birgegård, G; Engström-Laurent, A; Hultdin, M; Lundström, B; Samuelsson, J; Sundström, G; Wahlin, A	1
Cacciola, E; Cacciola, RR; Di Francesco, E; Giustolisi, R; Pezzella, F; Tibullo, D	1
Cheng, G; Lam, LW; Wong, RS	1
Chintagumpala, MM; Kennedy, LL; Steuber, CP	1
Griesshammer, M; Hehlmann, R; Lengfelder, E	1
Barbui, T; Brière, J; Dupuy, E; Finazzi, G; Kiladjian, JJ	1
Mesa, RA; Petitt, RM; Silverstein, MN; Solberg, LA; Tefferi, A	1
Beykirch, MK; Petrides, PE; Trapp, OM	1
Sréter, L	1
Oertel, MD	1
Chernoff, SG; Ruiz-Argüelles, GJ; Ruiz-Delgado, GJ; Ruiz-Reyes, G	1
Adam, H; Burkhard, R; Honegger, HP; Widmer, L	1
Silverstein, MN; Tefferi, A	2
Bennett, CL; Golub, RM; Weinberg, PO	1
Bellucci, S; Boval, B; Caen, J; Drouet, L; Legrand, C	1
Bashford, J; Brigden, MC; Bunce, I; Eliadis, P; Kelly, C; Mills, AK; Olsen, T; Rentoul, A; Seeley, G; Taylor, KM; Wright, SJ	1
Green, AR	1
Storen, EC; Tefferi, A	1
Kornblihtt, LI; Laguna, MS; Marta, RF; Molinas, FC	1
Briere, J; Guilmin, F	1
Bangerter, M; Griesshammer, M; Grünewald, M	1
Tefferi, A; Wright, CA	1
Hysing, J; Knutsen, H	1
Ikeda, Y	1
Tomer, A	1
Balduini, CL; Ferrari, A; Mazzucconi, MG	1
Hoagland, HC; McIntyre, KJ; Petitt, RM; Silverstein, MN	1
Frenkel, EP	1
Chintagumpala, MM; Fernbach, DJ; Mahoney, DH; Ogden, AK; Steuber, CP	1
Fleming, JS; Knight, RC; Petitt, RM; Schacter, LP; Silverstein, MN; Solberg, LA	1

Reviews

45 review(s) available for quinazolines and Hemorrhagic Thrombocythemia

Article	Year
SURPASS-ET: phase III study of ropeginterferon alfa-2b versus anagrelide as second-line therapy in essential thrombocythemia. Future oncology (London, England), 2022, Volume: 18, Issue:27 Topics: Clinical Trials, Phase III as Topic; Humans; Hydroxyurea; Multicenter Studies as Topic; Quinazolines; Randomized Controlled Trials as Topic; Thrombocythemia, Essential	2022
Thrombocytosis in children and adolescents-classification, diagnostic approach, and clinical management. Annals of hematology, 2021, Volume: 100, Issue:7 Topics: Adolescent; Adult; Age of Onset; Algorithms; Anticoagulants; Calreticulin; Child; Disease Management; Female; Germ-Line Mutation; Humans; Hydroxyurea; Interferon-alpha; Janus Kinase 2; Male; Myelodysplastic-Myeloproliferative Diseases; Platelet Count; Quinazolines; Receptors, Thrombopoietin; Severity of Illness Index; Thrombocythemia, Essential; Thrombocytosis; Thrombophilia	2021
[Treatment of essential thrombocythemia]. Medicina clinica, 2013, Sep-21, Volume: 141, Issue:6 Topics: Adult; Age Factors; Aged; Anticoagulants; Aspirin; Cell Transformation, Neoplastic; Disease Progression; Female; Hemorrhage; Heparin, Low-Molecular-Weight; Humans; Hydroxyurea; Intraoperative Complications; Janus Kinase 2; Leukemia, Myeloid, Acute; Life Expectancy; Male; Middle Aged; Mutation, Missense; Platelet Aggregation Inhibitors; Point Mutation; Pregnancy; Pregnancy Complications, Hematologic; Primary Myelofibrosis; Quinazolines; Risk Factors; Thrombocythemia, Essential; Thrombophilia	2013
Paediatric essential thrombocythaemia: clinical and molecular features, diagnosis and treatment. British journal of haematology, 2013, Volume: 163, Issue:3 Topics: Adolescent; Age of Onset; Anticoagulants; Child; Child, Preschool; Clone Cells; Disease Progression; GPI-Linked Proteins; Hemorrhage; Humans; Hydroxyurea; Incidence; Infant; Isoantigens; Janus Kinase 2; Leukemia, Myeloid, Acute; Platelet Aggregation Inhibitors; Point Mutation; Primary Myelofibrosis; Quinazolines; Receptors, Cell Surface; Risk Assessment; Symptom Assessment; Thrombocythemia, Essential; Thrombophilia	2013
Therapeutic options for patients with polycythemia vera and essential thrombocythemia refractory/resistant to hydroxyurea. Leukemia & lymphoma, 2014, Volume: 55, Issue:12 Topics: Antineoplastic Agents; Busulfan; Disease Management; Drug Resistance; Histone Deacetylase Inhibitors; Humans; Hydroxyurea; Interferon-alpha; Janus Kinase 2; Pipobroman; Platelet Aggregation Inhibitors; Polycythemia Vera; Protein Kinase Inhibitors; Quinazolines; Thrombocythemia, Essential; Treatment Outcome	2014
[Treatment strategy for myeloproliferative neoplasms]. [Rinsho ketsueki] The Japanese journal of clinical hematology, 2014, Volume: 55, Issue:10 Topics: Adrenal Cortex Hormones; Aspirin; Calreticulin; Carbamates; Clinical Trials as Topic; Drug Therapy, Combination; Hematopoietic Stem Cell Transplantation; Humans; Hydroxyurea; Immunosuppressive Agents; Janus Kinase 2; Molecular Targeted Therapy; Mutation; Nitriles; Platelet Aggregation Inhibitors; Polycythemia Vera; Primary Myelofibrosis; Prognosis; Pyrazoles; Pyrimidines; Quinazolines; Receptors, Thrombopoietin; Thalidomide; Thrombocythemia, Essential	2014
Anagrelide compared with hydroxyurea in essential thrombocythemia: a meta-analysis. Journal of thrombosis and thrombolysis, 2015, Volume: 40, Issue:4 Topics: Hemorrhage; Humans; Hydroxyurea; Quinazolines; Thrombocythemia, Essential; Thrombosis	2015
Essential Thrombocythemia: The Dermatologic Point of View. Clinical lymphoma, myeloma & leukemia, 2015, Volume: 15, Issue:12 Topics: Antineoplastic Agents; Humans; Hydroxyurea; Interferon-alpha; Quinazolines; Skin Diseases; Thrombocythemia, Essential	2015
Letting post-marketing bridge the evidence gap: the case of orphan drugs. BMJ (Clinical research ed.), 2016, Jun-22, Volume: 353 Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Barrett Esophagus; Cladribine; Dihematoporphyrin Ether; Ductus Arteriosus, Patent; Hepatolenticular Degeneration; Humans; Ibuprofen; Leukemia, Hairy Cell; Mitotane; Orphan Drug Production; Platelet Aggregation Inhibitors; Product Surveillance, Postmarketing; Quinazolines; Thrombocythemia, Essential; Zinc Acetate	2016
The Use of Anagrelide in Myeloproliferative Neoplasms, with Focus on Essential Thrombocythemia. Current hematologic malignancy reports, 2016, Volume: 11, Issue:5 Topics: Age Factors; Bone Marrow; Cardiovascular Diseases; Humans; Interferon-alpha; Myeloproliferative Disorders; Platelet Aggregation Inhibitors; Quinazolines; Tachycardia; Thrombocythemia, Essential	2016
Evidence and expertise in the management of polycythemia vera and essential thrombocythemia. Leukemia, 2008, Volume: 22, Issue:8 Topics: Aspirin; Humans; Hydroxyurea; Interferon-alpha; Janus Kinase 2; Mutation; Phlebotomy; Polycythemia Vera; Quinazolines; Risk Factors; Survival Analysis; Thrombocythemia, Essential	2008
Long-term management of thrombocytosis in essential thrombocythaemia. Annals of hematology, 2009, Volume: 88, Issue:1 Topics: Algorithms; Antineoplastic Agents; Aspirin; Female; Fibrinolytic Agents; Humans; Hydroxyurea; Interferon-alpha; Janus Kinase 2; Pregnancy; PubMed; Quinazolines; Randomized Controlled Trials as Topic; Thrombocythemia, Essential; Thrombocytosis	2009
Anagrelide treatment in early pregnancy in a patient with JAK2V617F-positive essential thrombocythemia: case report and literature review. Acta haematologica, 2009, Volume: 122, Issue:4 Topics: Adult; Amino Acid Substitution; Female; Fibrinolytic Agents; Humans; Infant, Newborn; Janus Kinase 2; Point Mutation; Pregnancy; Pregnancy Complications, Hematologic; Pregnancy Outcome; Quinazolines; Thrombocythemia, Essential	2009
Pathogenesis and management of essential thrombocythemia. Hematology. American Society of Hematology. Education Program, 2009 Topics: Acute Disease; Aged; Aspirin; Clone Cells; Disease Management; Disease Progression; Humans; Hydroxyurea; Interferon-alpha; Janus Kinase 2; Leukemia, Myeloid; Middle Aged; Models, Biological; Mutation, Missense; Polycythemia Vera; Primary Myelofibrosis; Prognosis; Protein Kinase Inhibitors; Quinazolines; Thrombocythemia, Essential; Thrombophilia	2009
Role of platelet counts in the management of essential thrombocythemia: experience with anagrelide. Expert review of hematology, 2009, Volume: 2, Issue:3 Topics: Blood Platelets; Humans; Platelet Aggregation Inhibitors; Platelet Count; Quinazolines; Risk Factors; Thrombocythemia, Essential	2009
How to manage essential thrombocythemia. Leukemia, 2012, Volume: 26, Issue:5 Topics: Female; Heparin, Low-Molecular-Weight; Humans; Hydroxyurea; Interferon-alpha; Pregnancy; Pregnancy Complications, Hematologic; Quinazolines; Risk Factors; Thrombocythemia, Essential	2012
Headache in essential thrombocythaemia. International journal of clinical practice, 2012, Volume: 66, Issue:10 Topics: Alkylating Agents; Analgesics; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Headache Disorders; Humans; Hydroxyurea; Immunologic Factors; Interferon-alpha; Phosphorus Radioisotopes; Platelet Aggregation Inhibitors; Quinazolines; Radiopharmaceuticals; Risk Factors; Thrombocythemia, Essential	2012
[Management of patients with essential thrombocythemia]. Medicina clinica, 2013, Mar-16, Volume: 140, Issue:6 Topics: Adult; Aged; Bone Marrow; Cytostatic Agents; Disease Management; Female; Genetic Predisposition to Disease; Hemorrhage; Humans; Interferon-alpha; Janus Kinase 2; Lactation; Male; Middle Aged; Platelet Aggregation Inhibitors; Point Mutation; Pregnancy; Pregnancy Complications, Hematologic; Quinazolines; Thrombocythemia, Essential; Thrombophilia	2013
Essential thrombocythemia: diagnosis and treatment, with special emphasis on the use of anagrelide. Hematology (Amsterdam, Netherlands), 2002, Volume: 7, Issue:3 Topics: Antineoplastic Agents; Blood Platelets; Contraindications; Humans; Platelet Aggregation Inhibitors; Quinazolines; Thrombocythemia, Essential; Treatment Outcome	2002
Essential thrombocythemia (ET): moving from palliation to cure. Hematology (Amsterdam, Netherlands), 2002, Volume: 7, Issue:6 Topics: Female; Humans; Hydroxyurea; Interferon alpha-2; Interferon-alpha; Male; Palliative Care; Pregnancy; Pregnancy Complications, Hematologic; Quinazolines; Recombinant Proteins; Thrombocythemia, Essential	2002
Indications for lowering platelet numbers in essential thrombocythemia. Seminars in hematology, 2003, Volume: 40, Issue:1 Suppl 1 Topics: Age Factors; Drug Therapy, Combination; Humans; Hydroxyurea; Interferon-alpha; Platelet Aggregation Inhibitors; Platelet Count; Quinazolines; Risk Factors; Thrombocythemia, Essential; Thrombosis	2003
Pharmacotherapy of essential thrombocythaemia: economic considerations. Expert opinion on pharmacotherapy, 2003, Volume: 4, Issue:9 Topics: Age Factors; Antineoplastic Agents; Aspirin; Clinical Trials, Phase II as Topic; Cost-Benefit Analysis; Humans; Hydroxyurea; Interferon-alpha; Pipobroman; Quinazolines; Risk Factors; Thrombocythemia, Essential	2003
Thrombocytosis. The New England journal of medicine, 2004, Mar-18, Volume: 350, Issue:12 Topics: Aspirin; Clone Cells; Diagnosis, Differential; Humans; Hydroxyurea; Interferon-alpha; Plasmapheresis; Platelet Aggregation Inhibitors; Quinazolines; Thrombocythemia, Essential; Thrombocytosis	2004
Management of the myeloproliferative disorders : distinguishing data from dogma. The hematology journal : the official journal of the European Haematology Association, 2004, Volume: 5 Suppl 3 Topics: Abnormalities, Drug-Induced; Adult; Aged; Anticoagulants; Contraindications; Female; Humans; Hydroxyurea; Interferon-alpha; Male; Middle Aged; Myeloproliferative Disorders; Phlebotomy; Polycythemia Vera; Pregnancy; Pregnancy Complications, Hematologic; Prognosis; Quinazolines; Randomized Controlled Trials as Topic; Thrombocythemia, Essential; Thrombophilia	2004
The leukemia controversy in myeloproliferative disorders: is it a natural progression of disease, a secondary sequela of therapy, or a combination of both? Seminars in hematology, 2004, Volume: 41, Issue:2 Suppl 3 Topics: Age Factors; Aged; Antineoplastic Agents, Alkylating; Antiviral Agents; Disease Progression; Female; Humans; Hydroxyurea; Interferon-alpha; Leukemia; Male; Middle Aged; Platelet Aggregation Inhibitors; Polycythemia Vera; Quinazolines; Risk Factors; Thrombocythemia, Essential; Thrombosis	2004
Anagrelide: a decade of clinical experience with its use for the treatment of primary thrombocythaemia. Expert opinion on pharmacotherapy, 2004, Volume: 5, Issue:8 Topics: Animals; Carcinogens; Clinical Trials as Topic; Drug Therapy, Combination; Heart Diseases; Humans; Hydroxyurea; Interferon Type I; Mutagens; Platelet Aggregation Inhibitors; Platelet Count; Quinazolines; Recombinant Proteins; Thrombocythemia, Essential; Thromboembolism	2004
A critical review of anagrelide therapy in essential thrombocythemia and related disorders. Leukemia & lymphoma, 2005, Volume: 46, Issue:5 Topics: Clinical Trials as Topic; Humans; Hydroxyurea; Quinazolines; Thrombocythemia, Essential; Thrombocytosis	2005
[Treatment of essential thrombocythemia]. La Revue de medecine interne, 2005, Volume: 26, Issue:12 Topics: Aspirin; Enzyme Inhibitors; Hemorrhage; Humans; Hydroxyurea; Immunologic Factors; Interferon-alpha; Platelet Aggregation Inhibitors; Quinazolines; Randomized Controlled Trials as Topic; Risk Factors; Thrombocythemia, Essential	2005
Anagrelide: a review of its use in the management of essential thrombocythaemia. Drugs, 2006, Volume: 66, Issue:1 Topics: Blood Platelets; Drug Tolerance; Hematologic Agents; Humans; Platelet Count; Quinazolines; Randomized Controlled Trials as Topic; Thrombocythemia, Essential	2006
Management of essential thrombocythemia: implications of the medical research council primary thrombocythemia 1 trial. Seminars in thrombosis and hemostasis, 2006, Volume: 32, Issue:3 Topics: Disease Management; Humans; Hydroxyurea; Quinazolines; Randomized Controlled Trials as Topic; Thrombocythemia, Essential; Treatment Outcome	2006
Anagrelide: what was new in 2004 and 2005? Seminars in thrombosis and hemostasis, 2006, Volume: 32, Issue:4 Pt 2 Topics: Antineoplastic Agents; Aspirin; Blood Platelets; Clinical Trials, Phase III as Topic; Drug Therapy, Combination; Female; Fibrinolytic Agents; Hemorrhage; History, 21st Century; Humans; Hydroxyurea; Male; Megakaryocytes; Platelet Aggregation Inhibitors; Pregnancy; Pregnancy Complications, Hematologic; Quinazolines; Randomized Controlled Trials as Topic; Signal Transduction; Thrombocythemia, Essential	2006
Update on diagnosis and management of essential thrombocythemia. Seminars in thrombosis and hemostasis, 2006, Volume: 32, Issue:4 Pt 2 Topics: Age Factors; Antineoplastic Agents; Aspirin; Drug Antagonism; Female; Fibrinolytic Agents; Hemorrhage; Humans; Hydroxyurea; Interferon-alpha; Life Expectancy; Male; Quinazolines; Risk Factors; Thrombocythemia, Essential	2006
[Primary thrombocythemia: diagnosis and therapy]. Medizinische Klinik (Munich, Germany : 1983), 2006, Aug-15, Volume: 101, Issue:8 Topics: Adult; Aged; Aspirin; Child; Diagnosis, Differential; Drug Therapy, Combination; Enzyme Inhibitors; Female; Follow-Up Studies; Humans; Hydroxyurea; Immunologic Factors; Interferon-alpha; Male; Mutation; Platelet Aggregation Inhibitors; Platelet Count; Pregnancy; Pregnancy Complications, Hematologic; Primary Prevention; Prospective Studies; Quinazolines; Randomized Controlled Trials as Topic; Risk Assessment; Risk Factors; Thrombocythemia, Essential; Time Factors	2006
Treatment of essential thrombocythemia with anagrelide. The Journal of pediatrics, 1995, Volume: 127, Issue:3 Topics: Adolescent; Blood Cell Count; Bone Marrow Examination; Child; Drug Evaluation; Female; Humans; Male; Platelet Aggregation; Platelet Aggregation Inhibitors; Quinazolines; Thrombocythemia, Essential	1995
Treatment strategies in essential thrombocythemia. A critical appraisal of various experiences in different centers. Leukemia & lymphoma, 1996, Volume: 22 Suppl 1 Topics: Adult; Aged; Alkylating Agents; Anemia, Megaloblastic; Arrhythmias, Cardiac; Bone Marrow Diseases; Busulfan; Female; Hemorrhage; Humans; Hydroxyurea; Immunologic Factors; Incidence; Interferon-alpha; Ischemic Attack, Transient; Leukemia; Male; Middle Aged; Pipobroman; Platelet Aggregation Inhibitors; Platelet Count; Prognosis; Quinazolines; Risk Factors; Thrombocythemia, Essential; Thrombosis	1996
Anagrelide as a new platelet-lowering agent in essential thrombocythemia: mechanism of actin, efficacy, toxicity, current indications. Seminars in thrombosis and hemostasis, 1997, Volume: 23, Issue:4 Topics: Animals; Bone Marrow; Cardiovascular Diseases; Clinical Trials as Topic; Cohort Studies; Hematopoiesis; Hemodynamics; Humans; Megakaryocytes; Middle Aged; Myeloproliferative Disorders; Platelet Aggregation Inhibitors; Quinazolines; Thrombocythemia, Essential; Thrombosis	1997
Anagrelide, a selective thrombocytopenic agent. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 1998, Oct-01, Volume: 55, Issue:19 Topics: Humans; Platelet Aggregation Inhibitors; Quinazolines; Thrombocythemia, Essential	1998
Treatment of essential thrombocythemia with anagrelide. Seminars in hematology, 1999, Volume: 36, Issue:1 Suppl 2 Topics: Humans; Platelet Aggregation Inhibitors; Quinazolines; Thrombocythemia, Essential	1999
Treatment of polycythaemia vera and essential thrombocythaemia. Bailliere's clinical haematology, 1998, Volume: 11, Issue:4 Topics: Adult; Aged; Aspirin; Chlorambucil; Disease Progression; Female; Hemorrhage; Humans; Hydroxyurea; Interferon-alpha; Leukemia, Myeloid; Leukemia, Radiation-Induced; Male; Middle Aged; Phlebotomy; Phosphorus Radioisotopes; Pipobroman; Polycythemia Vera; Primary Myelofibrosis; Prospective Studies; Quinazolines; Thrombocythemia, Essential; Thrombosis	1998
The pathogenesis and management of essential thrombocythaemia. Haematologica, 1999, Volume: 84 Suppl EHA-4 Topics: Acute Disease; Alkylating Agents; Aspirin; Cardiovascular Diseases; Clone Cells; Gene Expression; Hemorrhage; Humans; Hydroxyurea; Leukemia, Myeloid; Megakaryocytes; Platelet Aggregation Inhibitors; Quinazolines; Risk; Thrombocythemia, Essential; Thrombophilia	1999
Management of patients with essential thrombocythemia: current concepts and perspectives. Pathologie-biologie, 2001, Volume: 49, Issue:2 Topics: Adult; Aged; Aspirin; Case Management; Clinical Trials as Topic; Diagnosis, Differential; Disease Progression; Female; Hemorrhagic Disorders; Humans; Hydroxyurea; Interferons; Leukemia; Male; Middle Aged; Pipobroman; Platelet Aggregation Inhibitors; Platelet Count; Pregnancy; Pregnancy Complications, Hematologic; Prospective Studies; Quinazolines; Risk; Safety; Thrombocythemia, Essential; Thrombophilia	2001
Current treatment practice for essential thrombocythaemia in adults. Expert opinion on pharmacotherapy, 2001, Volume: 2, Issue:3 Topics: Adult; Aspirin; Humans; Hydroxyurea; Interferon-alpha; Pipobroman; Prognosis; Quinazolines; Thrombocythemia, Essential	2001
A single institutional experience with 43 pregnancies in essential thrombocythemia. European journal of haematology, 2001, Volume: 66, Issue:3 Topics: Abortion, Induced; Abortion, Spontaneous; Abruptio Placentae; Adult; Anticoagulants; Aspirin; Busulfan; Erythromelalgia; Female; Fetal Death; Follow-Up Studies; Heparin; Humans; Hydroxyurea; Migraine Disorders; Obstetric Labor, Premature; Phosphorus Radioisotopes; Platelet Aggregation Inhibitors; Platelet Count; Plateletpheresis; Pregnancy; Pregnancy Complications, Hematologic; Pregnancy Outcome; Pregnancy Trimester, First; Pregnancy, Ectopic; Pregnancy, High-Risk; Quinazolines; Retrospective Studies; Risk; Thrombocythemia, Essential; Uterine Hemorrhage	2001
[Essential thrombocythemia: therapy with anagrelide]. Haematologica, 1991, Volume: 76 Suppl 3 Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Drug Evaluation; Female; Hematopoiesis; Humans; Male; Megakaryocytes; Phospholipases A; Platelet Aggregation Inhibitors; Platelet Count; Quinazolines; Thrombocythemia, Essential	1991
The clinical spectrum of thrombocytosis and thrombocythemia. The American journal of the medical sciences, 1991, Volume: 301, Issue:1 Topics: Blood Platelets; Cytokines; Hematopoiesis; Humans; Hydroxyurea; Interferon Type I; Megakaryocytes; Platelet Aggregation; Platelet Count; Quinazolines; Thrombocythemia, Essential; Thrombocytosis	1991

Trials

21 trial(s) available for quinazolines and Hemorrhagic Thrombocythemia

Article	Year
Cytoreductive treatment in patients with CALR-mutated essential thrombocythaemia: a study comparing indications and efficacy among genotypes from the Spanish Registry of Essential Thrombocythaemia. British journal of haematology, 2021, Volume: 192, Issue:6 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amino Acid Substitution; Calreticulin; Child; Female; Follow-Up Studies; Genotype; Humans; Hydroxyurea; Janus Kinase 2; Male; Middle Aged; Mutation, Missense; Quinazolines; Registries; Spain; Thrombocythemia, Essential	2021
Cardiovascular Safety of Anagrelide Hydrochloride versus Hydroxyurea in Essential Thrombocythaemia. Cardiovascular toxicology, 2021, Volume: 21, Issue:3 Topics: Adolescent; Adult; Aged; Biopsy; Blood Platelets; Bone Marrow Examination; Echocardiography; Europe; Female; Humans; Hydroxyurea; Male; Middle Aged; Platelet Count; Quinazolines; Stroke Volume; Thrombocythemia, Essential; Time Factors; Treatment Outcome; Ventricular Dysfunction, Left; Ventricular Function, Left; Young Adult	2021
Leukemic transformation and second cancers in 3649 patients with high-risk essential thrombocythemia in the EXELS study. Leukemia research, 2018, Volume: 74 Topics: Adult; Aged; Aged, 80 and over; Cell Transformation, Neoplastic; Female; Humans; Hydroxyurea; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoplasms, Second Primary; Quinazolines; Thrombocythemia, Essential	2018
Characterization of different regimens for initiating anagrelide in patients with essential thrombocythemia who are intolerant or refractory to their current cytoreductive therapy: results from the multicenter FOX study of 177 patients in France. European journal of haematology, 2014, Volume: 92, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Drug Substitution; Female; France; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Platelet Count; Quinazolines; Retreatment; Thrombocythemia, Essential; Time Factors; Treatment Outcome; Young Adult	2014
Combination therapy of hydroxycarbamide with anagrelide in patients with essential thrombocythemia in the evaluation of Xagrid(R) efficacy and long-term safety study. Haematologica, 2014, Volume: 99, Issue:4 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Blood Cell Count; Drug Therapy, Combination; Female; Humans; Hydroxyurea; Interferons; Male; Middle Aged; Quinazolines; Thrombocythemia, Essential; Treatment Outcome; Young Adult	2014
Phase III, single-arm study investigating the efficacy, safety, and tolerability of anagrelide as a second-line treatment in high-risk Japanese patients with essential thrombocythemia. International journal of hematology, 2014, Volume: 100, Issue:4 Topics: Adult; Aged; Aged, 80 and over; Asian People; Blood Platelets; Female; Fibrinolytic Agents; Humans; Japan; Male; Middle Aged; Platelet Count; Quinazolines; Risk Factors; Thrombocythemia, Essential; Time Factors	2014
Anagrelide treatment and cardiovascular monitoring in essential thrombocythemia. A prospective observational study. Leukemia research, 2015, Volume: 39, Issue:6 Topics: Adult; Aged; Cardiovascular Diseases; Electrocardiography; Female; Follow-Up Studies; Humans; Male; Middle Aged; Monitoring, Physiologic; Natriuretic Peptide, Brain; Peptide Fragments; Platelet Aggregation Inhibitors; Prospective Studies; Quinazolines; Thrombocythemia, Essential; Troponin I	2015
[Efficacy and safety of anagrelide in treatment of essential thrombocythemia: multicenter, randomized controlled clinical trial]. Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi, 2015, Volume: 36, Issue:7 Topics: Humans; Hydroxyurea; Platelet Aggregation Inhibitors; Platelet Count; Quinazolines; Thrombocythemia, Essential; Treatment Outcome	2015
Reticulin accumulation in essential thrombocythemia: prognostic significance and relationship to therapy. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009, Jun-20, Volume: 27, Issue:18 Topics: Biomarkers; Bone Marrow; Hemoglobins; Hemorrhage; Humans; Hydroxyurea; Leukocyte Count; Platelet Aggregation Inhibitors; Platelet Count; Primary Myelofibrosis; Prognosis; Prospective Studies; Quinazolines; Reticulin; Thrombocythemia, Essential; Thrombosis	2009
[The results of patients with essentials thrombocythemia and other myeloproliferation-related thrombocythemia--a report of patients treated with Thromboreductin]. Vnitrni lekarstvi, 2009, Volume: 55, Issue:11 Topics: Adult; Aged; Aged, 80 and over; Female; Humans; Male; Middle Aged; Myeloproliferative Disorders; Platelet Aggregation Inhibitors; Quinazolines; Thrombocythemia, Essential; Thrombocytosis	2009
Pharmacokinetics and tolerability of anagrelide hydrochloride in young (18 - 50 years) and elderly (≥ 65 years) patients with essential thrombocythemia. International journal of clinical pharmacology and therapeutics, 2012, Volume: 50, Issue:11 Topics: Adolescent; Adult; Age Factors; Aged; Area Under Curve; Biotransformation; Europe; Female; Half-Life; Hematologic Agents; Humans; Hydroxylation; Male; Metabolic Clearance Rate; Middle Aged; Models, Biological; Platelet Count; Quinazolines; Thrombocythemia, Essential; Thrombopoiesis; Treatment Outcome; Young Adult	2012
Efficacy and safety of cytoreductive therapies in patients with essential thrombocythaemia aged >80 years: an interim analysis of the EXELS study. Clinical drug investigation, 2013, Volume: 33, Issue:1 Topics: Age Factors; Aged, 80 and over; Analysis of Variance; Chi-Square Distribution; Drug Substitution; Europe; Female; Hematologic Agents; Humans; Hydroxyurea; Kaplan-Meier Estimate; Male; Platelet Count; Prospective Studies; Quinazolines; Risk Factors; Thrombocythemia, Essential; Time Factors; Treatment Outcome	2013
Cytoreductive treatment patterns for essential thrombocythemia in Europe. Analysis of 3643 patients in the EXELS study. Leukemia research, 2013, Volume: 37, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Europe; Female; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Quinazolines; Risk Factors; Thrombocythemia, Essential; Treatment Outcome; Young Adult	2013
Anagrelide compared with hydroxyurea in WHO-classified essential thrombocythemia: the ANAHYDRET Study, a randomized controlled trial. Blood, 2013, Mar-07, Volume: 121, Issue:10 Topics: Adult; Aged; Aged, 80 and over; Female; Follow-Up Studies; Humans; Hydroxyurea; Male; Maximum Tolerated Dose; Middle Aged; Nucleic Acid Synthesis Inhibitors; Platelet Aggregation Inhibitors; Prognosis; Prospective Studies; Quinazolines; Retrospective Studies; Single-Blind Method; Thrombocythemia, Essential; World Health Organization; Young Adult	2013
Open-label, dose-titration and continuation study to assess efficacy, safety, and pharmacokinetics of anagrelide in treatment-naïve Japanese patients with essential thrombocythemia. International journal of hematology, 2013, Volume: 97, Issue:3 Topics: Adult; Aged; Asian People; Female; Follow-Up Studies; Humans; Japan; Male; Middle Aged; Platelet Aggregation Inhibitors; Platelet Count; Quinazolines; Thrombocythemia, Essential; Time Factors	2013
Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. The New England journal of medicine, 2005, Jul-07, Volume: 353, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Aspirin; Drug Therapy, Combination; Female; Follow-Up Studies; Hemorrhage; Humans; Hydroxyurea; Leukemia, Myeloid, Acute; Male; Middle Aged; Platelet Aggregation Inhibitors; Platelet Count; Primary Myelofibrosis; Quinazolines; Thrombocythemia, Essential; Thrombosis	2005
[Megakaryopoietic cytokine levels in patients with essential thrombocythemia and their relationship with clinical and biochemical features]. Medicina, 2006, Volume: 66, Issue:6 Topics: Enzyme-Linked Immunosorbent Assay; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Interleukin-3; Megakaryocytes; Platelet Aggregation; Platelet Aggregation Inhibitors; Quinazolines; Retrospective Studies; Statistics, Nonparametric; Stem Cell Factor; Thrombocythemia, Essential; Thrombocytosis; Thrombopoiesis; Thrombopoietin	2006
Progression of bone marrow fibrosis in patients with essential thrombocythemia and polycythemia vera during anagrelide treatment. Medical oncology (Northwood, London, England), 2007, Volume: 24, Issue:1 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Disease Progression; Female; Fibrinolytic Agents; Humans; Hyaluronic Acid; Male; Middle Aged; Polycythemia Vera; Primary Myelofibrosis; Prognosis; Prospective Studies; Quinazolines; Reticulin; Thrombocythemia, Essential; Thrombocytosis	2007
Effect of anagrelide on platelet coagulant function in patients with essential thrombocythemia. Acta haematologica, 2007, Volume: 118, Issue:4 Topics: Adult; Aged; Antithrombin III; Aspirin; Drug Therapy, Combination; Female; Fibrin Fibrinogen Degradation Products; Hemorrhage; Humans; Hydroxyurea; Male; Middle Aged; Peptide Fragments; Peptide Hydrolases; Platelet Activation; Platelet Aggregation Inhibitors; Platelet Count; Platelet Factor 4; Prothrombin; Quinazolines; Thrombocythemia, Essential; Thrombosis	2007
Efficacy, safety and tolerability of anagrelide in the treatment of essential thrombocythaemia. Australian and New Zealand journal of medicine, 1999, Volume: 29, Issue:1 Topics: Adolescent; Adult; Aged; Female; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Platelet Count; Prospective Studies; Quinazolines; Thrombocythemia, Essential	1999
[Essential thrombocythemia: therapy with anagrelide]. Haematologica, 1991, Volume: 76 Suppl 3 Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Drug Evaluation; Female; Hematopoiesis; Humans; Male; Megakaryocytes; Phospholipases A; Platelet Aggregation Inhibitors; Platelet Count; Quinazolines; Thrombocythemia, Essential	1991

Other Studies

98 other study(ies) available for quinazolines and Hemorrhagic Thrombocythemia

Article	Year
A toe ulcer in a patient with essential thrombocythemia successfully treated with a combination of anagrelide and prednisolone. Dermatologic therapy, 2022, Volume: 35, Issue:2 Topics: Humans; Prednisolone; Quinazolines; Thrombocythemia, Essential; Toes; Ulcer	2022
Anagrelide for platelet-directed cytoreduction in polycythemia vera: Insights into utility and safety outcomes from a large multi-center database. Leukemia research, 2022, Volume: 119 Topics: Cytoreduction Surgical Procedures; Humans; Polycythemia Vera; Quinazolines; Thrombocythemia, Essential; Thrombocytosis; Thrombosis	2022
Review of the risk of thrombosis or bleeding upon abrupt anagrelide discontinuation in patients with essential thrombocythemia. Annals of hematology, 2022, Volume: 101, Issue:11 Topics: Hemorrhage; Humans; Platelet Aggregation Inhibitors; Quinazolines; Thrombocythemia, Essential; Thrombosis	2022
Anagrelide in essential thrombocythemia: Efficacy and long-term consequences in young patient population. Leukemia research, 2022, Volume: 123 Topics: Child; Erythropoietin; Humans; Platelet Aggregation Inhibitors; Primary Myelofibrosis; Quinazolines; Thrombocythemia, Essential	2022
Anagrelide with low-dose aspirin promptly epithelized ulceronecrotic lesion secondary to essential thrombocythemia. The Journal of dermatology, 2020, Volume: 47, Issue:5 Topics: Aspirin; Bone Marrow; Dose-Response Relationship, Drug; Drug Therapy, Combination; Humans; Janus Kinase 2; Karyotyping; Male; Middle Aged; Mutation; Necrosis; Quinazolines; Re-Epithelialization; Skin; Skin Ulcer; Thrombocythemia, Essential; Toes; Treatment Outcome	2020
Comparison of starting doses of anagrelide as a first-line therapy in patients with cytoreductive therapy-naïve essential thrombocythemia: difference between starting at 0.5 and 1.0 mg/day. International journal of hematology, 2020, Volume: 112, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Cytoreduction Surgical Procedures; Dose-Response Relationship, Drug; Female; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Quinazolines; Retrospective Studies; Safety; Thrombocythemia, Essential; Treatment Outcome; Young Adult	2020
Anagrelide in Essential Thrombocythemia (ET): Results from 150 patients over 25 years by the "Ph1-negative Myeloproliferative Neoplasms Latium Group". European journal of haematology, 2020, Volume: 105, Issue:3 Topics: Adult; Age Factors; Aged; Aged, 80 and over; Anemia; Disease Management; Disease Susceptibility; Drug Substitution; Female; Follow-Up Studies; Health Care Surveys; Humans; Italy; Male; Middle Aged; Pregnancy; Pregnancy Complications, Hematologic; Prognosis; Quinazolines; Retreatment; Retrospective Studies; Thrombocythemia, Essential; Thrombosis; Treatment Outcome; Young Adult	2020
Anagrelide influences thrombotic risk, and prolongs progression-free and overall survival in essential thrombocythaemia vs hydroxyurea plus aspirin. European journal of haematology, 2020, Volume: 105, Issue:4 Topics: Aspirin; Drug Therapy, Combination; Health Care Surveys; Humans; Hungary; Hydroxyurea; Quinazolines; Registries; Thrombocythemia, Essential; Thrombosis; Treatment Outcome	2020
Acute Myocardial Infarction in an Adolescent Receiving Anagrelide for Essential Thrombocythemia with Underlying Persistent Coronary Endothelial Dysfunction. International heart journal, 2020, Nov-28, Volume: 61, Issue:6 Topics: Acetylcholine; Adolescent; Coronary Angiography; Coronary Vessels; Echocardiography; Endothelium, Vascular; Fibrinolytic Agents; Fibrosis; Heart Function Tests; Humans; Janus Kinase 2; Magnetic Resonance Imaging; Male; Nitroglycerin; Percutaneous Coronary Intervention; Quinazolines; Radionuclide Imaging; ST Elevation Myocardial Infarction; Thrombectomy; Thrombocythemia, Essential; Tomography, Optical Coherence; Tunica Intima; Vasodilator Agents	2020
Treatment of Essential Thrombocythemia with Anagrelide Is Associated with an Increased Risk of Worsened Kidney Function. Pharmacology, 2021, Volume: 106, Issue:5-6 Topics: Aged; Calreticulin; Creatinine; Disease Progression; Female; Humans; Hydroxyurea; Janus Kinase 2; Kidney Diseases; Male; Middle Aged; Mutation; Platelet Aggregation Inhibitors; Quinazolines; Retrospective Studies; Risk Factors; Thrombocythemia, Essential; Treatment Outcome	2021
Modifying the Effects of Cytoreductive Drugs on Kidney Function in Myeloproliferative Neoplasms. Pharmacology, 2021, Volume: 106, Issue:7-8 Topics: Humans; Hydroxyurea; Kidney Function Tests; Myeloproliferative Disorders; Platelet Aggregation Inhibitors; Quinazolines; Thrombocythemia, Essential	2021
Drug-induced interstitial pneumonitis in essential thrombocythemia treated with anagrelide. [Rinsho ketsueki] The Japanese journal of clinical hematology, 2017, Volume: 58, Issue:2 Topics: Aged; Female; Humans; Lung Diseases, Interstitial; Platelet Aggregation Inhibitors; Pneumonia; Quinazolines; Thrombocythemia, Essential; Treatment Outcome	2017
Hemorrhage and Infarction of the Conjunctiva and Orbit in Essential Thrombocythemia. The Journal of craniofacial surgery, 2017, Volume: 28, Issue:3 Topics: Aged, 80 and over; Biopsy; Conjunctiva; Eye Hemorrhage; Female; Hematologic Agents; Humans; Hydroxyurea; Orbit; Quinazolines; Thrombocythemia, Essential; Thrombosis; Tomography, X-Ray Computed; Treatment Outcome; Visual Acuity	2017
Role of treatment on the development of secondary malignancies in patients with essential thrombocythemia. Cancer medicine, 2017, Volume: 6, Issue:6 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Alkylating Agents; Antineoplastic Combined Chemotherapy Protocols; Female; Fibrinolytic Agents; Humans; Hydroxyurea; Interferon-alpha; Male; Middle Aged; Neoplasms, Second Primary; Quinazolines; Thrombocythemia, Essential; Young Adult	2017
Efficacy and safety of anagrelide in childhood essential thrombocythemia. Pediatrics international : official journal of the Japan Pediatric Society, 2017, Volume: 59, Issue:9 Topics: Child; Female; Humans; Platelet Aggregation Inhibitors; Quinazolines; Thrombocythemia, Essential	2017
Is anagrelide safe during pregnancy? Journal of gynecology obstetrics and human reproduction, 2017, Volume: 46, Issue:9 Topics: Abortion, Spontaneous; Adult; Female; Humans; Platelet Aggregation Inhibitors; Pregnancy; Pregnancy Complications, Hematologic; Quinazolines; Thrombocythemia, Essential; Uterine Hemorrhage	2017
Ventricular tachyarrhythmia in a 78-year-old woman with essential thrombocythaemia. BMJ case reports, 2018, Feb-08, Volume: 2018 Topics: Age Factors; Aged; Electrocardiography; Female; Humans; Hydroxyurea; Platelet Aggregation Inhibitors; Quinazolines; Risk Factors; Tachycardia, Ventricular; Thrombocythemia, Essential	2018
Anagrelide and the CALR mutation allele burden in essential thrombocythemia. Experimental oncology, 2018, Volume: 40, Issue:2 Topics: Aged; Alleles; Calreticulin; Humans; Male; Mutation; Platelet Aggregation Inhibitors; Platelet Count; Quinazolines; Thrombocythemia, Essential	2018
Decreased survival and increased rate of fibrotic progression in essential thrombocythemia chronicled after the FDA approval date of anagrelide. American journal of hematology, 2019, Volume: 94, Issue:1 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Bone Marrow; Disease Progression; Disease-Free Survival; Drug Approval; Female; Fibrosis; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Mortality; Platelet Aggregation Inhibitors; Polycythemia Vera; Primary Myelofibrosis; Prognosis; Proportional Hazards Models; Quinazolines; Retrospective Studies; Severity of Illness Index; Thrombocythemia, Essential; Thrombosis; Treatment Outcome; Young Adult	2019
Acute ischemic stroke in the setting of essential thrombocytemia (clinical cases). Terapevticheskii arkhiv, 2018, Aug-17, Volume: 90, Issue:7 Topics: Brain Ischemia; Cerebrovascular Circulation; Female; Gene Frequency; Humans; Janus Kinase 2; Middle Aged; Platelet Aggregation Inhibitors; Platelet Count; Quinazolines; Stroke; Thrombocythemia, Essential; Treatment Outcome	2018
Efficacy and safety of anagrelide as a first-line drug in cytoreductive treatment-naïve essential thrombocythemia patients in a real-world setting. European journal of haematology, 2019, Volume: 103, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Biomarkers; Disease Progression; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Mutation; Platelet Aggregation Inhibitors; Platelet Count; Quinazolines; Risk Factors; Thrombocythemia, Essential; Treatment Outcome; Young Adult	2019
Clinical Evaluation of the Efficacy and Safety of Anagrelide Used with or without Hydroxycarbamide in Japanese Patients with Essential Thrombocythemia-A Retrospective Single-Center Study of 35 Cases. Gan to kagaku ryoho. Cancer & chemotherapy, 2019, Volume: 46, Issue:7 Topics: Antineoplastic Combined Chemotherapy Protocols; Humans; Hydroxyurea; Japan; Quinazolines; Retrospective Studies; Thrombocythemia, Essential	2019
The therapeutic goals of essential thrombocythemia under the clouds of over-treatment and under-treatment. Expert opinion on pharmacotherapy, 2013, Volume: 14, Issue:11 Topics: Aspirin; Fibrinolytic Agents; Humans; Hydroxyurea; Interferon-alpha; Platelet Aggregation Inhibitors; Quinazolines; Risk Assessment; Thrombocythemia, Essential	2013
[The effectiveness of anagrelide treatment in patients with Ph negative myeloproliferative diseases: influence on the incidence of thrombosis in the data from the Registry of patients with essential thrombocythemia and thrombocythemia associated with othe Vnitrni lekarstvi, 2013, Volume: 59, Issue:6 Topics: Adult; Aged; Czech Republic; Female; Fibrinolytic Agents; Humans; Incidence; Male; Middle Aged; Myeloproliferative Disorders; Quinazolines; Registries; Thrombocythemia, Essential; Thrombosis	2013
Essential thrombocytemia progressing to Ph+ chronic myeloid leukemia with megakaryoblastic blasts, following anagrelide withdrawal. Platelets, 2014, Volume: 25, Issue:8 Topics: Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Megakaryocyte Progenitor Cells; Platelet Aggregation Inhibitors; Quinazolines; Thrombocythemia, Essential	2014
Successful long-term treatment of Philadelphia chromosome-negative myeloproliferative neoplasms with combination of hydroxyurea and anagrelide. Clinical lymphoma, myeloma & leukemia, 2013, Volume: 13 Suppl 2 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Hydroxyurea; Male; Middle Aged; Myeloproliferative Disorders; Philadelphia Chromosome; Polycythemia Vera; Quinazolines; Retrospective Studies; Thrombocythemia, Essential; Thrombosis	2013
Successful management of acute bleeding in essential thrombocythemia using automated cell separator. Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis, 2014, Volume: 50, Issue:1 Topics: Administration, Oral; Adolescent; Automation; Blood Platelets; Body Weight; Cell Separation; Female; Hemorrhage; Humans; Hydroxyurea; Platelet Count; Quinazolines; Thrombocythemia, Essential; Thrombocytosis	2014
Essential differences in clinical and bone marrow features in BCR/ABL-positive thrombocythemia compared to thrombocythemia in the BCR/ABL-negative myeloproliferative neoplasms essential thrombocythemia and polycythemia vera. Acta haematologica, 2015, Volume: 133, Issue:1 Topics: Aged; Alleles; Benzamides; Biopsy; Bone Marrow; Diagnosis, Differential; Drug Therapy, Combination; Female; Fusion Proteins, bcr-abl; Humans; Hydroxyurea; Imatinib Mesylate; Janus Kinase 2; Male; Middle Aged; Mutation; Myeloproliferative Disorders; Piperazines; Platelet Count; Polycythemia Vera; Pyrimidines; Quinazolines; Thrombocythemia, Essential; Treatment Outcome	2015
Anagrelide platelet-lowering effect is due to inhibition of both megakaryocyte maturation and proplatelet formation: insight into potential mechanisms. Journal of thrombosis and haemostasis : JTH, 2015, Volume: 13, Issue:4 Topics: Blood Platelets; Case-Control Studies; Cell Adhesion Molecules; Cells, Cultured; Cyclic AMP; Dose-Response Relationship, Drug; Fetal Blood; Hematopoietic Stem Cells; Heterocyclic Compounds, 4 or More Rings; Humans; Megakaryocytes; Microfilament Proteins; Myosins; Phosphodiesterase 3 Inhibitors; Phosphoproteins; Phosphorylation; Platelet Aggregation Inhibitors; Quinazolines; Signal Transduction; Thrombocythemia, Essential; Thrombopoiesis; Time Factors; Transcription Factors	2015
Essential thrombocythaemia. Hematology (Amsterdam, Netherlands), 2015, Volume: 20, Issue:2 Topics: Age Factors; Antineoplastic Agents; Blood Platelets; Calreticulin; Gene Expression; Humans; Hydroxyurea; Immunologic Factors; Interferon-alpha; Janus Kinase 2; Mutation; Platelet Aggregation Inhibitors; Quinazolines; Receptors, Thrombopoietin; Risk Factors; Thrombocythemia, Essential	2015
Prediction of thrombotic and hemorrhagic events during polycythemia vera or essential thrombocythemia based on leukocyte burden. Thrombosis research, 2015, Volume: 135, Issue:5 Topics: Adult; Aged; Aged, 80 and over; Area Under Curve; Blood Cell Count; Comorbidity; Databases, Factual; Female; Follow-Up Studies; Hemorrhage; Hemorrhagic Disorders; Humans; Hydroxyurea; Leukocyte Count; Male; Middle Aged; Phlebotomy; Platelet Aggregation Inhibitors; Polycythemia Vera; Prognosis; Quinazolines; Retrospective Studies; Risk Factors; Thrombocythemia, Essential; Thrombophilia; Thrombosis; Young Adult	2015
Impact of JAK2(V617F) mutation status on treatment response to anagrelide in essential thrombocythemia: an observational, hypothesis-generating study. Drug design, development and therapy, 2015, Volume: 9 Topics: Adult; Aged; Aged, 80 and over; Alleles; Blood Platelets; Female; Humans; Janus Kinase 2; Male; Middle Aged; Mutation; Platelet Aggregation Inhibitors; Quinazolines; Thrombocythemia, Essential; Treatment Outcome	2015
Long-term follow-up of essential thrombocythemia patients treated with anagrelide: subgroup analysis according to JAK2/CALR/MPL mutational status. European journal of haematology, 2016, Volume: 96, Issue:4 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anemia; Calreticulin; Child; Female; Follow-Up Studies; Gene Expression; Humans; Janus Kinase 2; Male; Middle Aged; Mutation; Platelet Aggregation Inhibitors; Primary Myelofibrosis; Quinazolines; Receptors, Thrombopoietin; Retrospective Studies; Thrombocythemia, Essential	2016
JAK2+ Essential Thrombocythemia in a Young Girl With Budd-Chiari Syndrome: Diagnostic and Therapeutic Considerations When Adult Disease Strikes the Young. Journal of pediatric hematology/oncology, 2016, Volume: 38, Issue:1 Topics: Budd-Chiari Syndrome; Child; Female; Humans; Janus Kinase 2; Liver Transplantation; Platelet Aggregation Inhibitors; Quinazolines; Splenectomy; Thrombocythemia, Essential	2016
[Treatment outcome of patients with essential thrombocythemia at our department in Hungary]. Orvosi hetilap, 2016, Feb-28, Volume: 157, Issue:9 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Hungary; Hydroxyurea; Interferons; Male; Middle Aged; Platelet Aggregation Inhibitors; Quinazolines; Survival Analysis; Thrombocythemia, Essential; Treatment Failure; Treatment Outcome	2016
Current opinion and consensus statement regarding the diagnosis, prognosis, and treatment of patients with essential thrombocythemia: a survey of the Spanish Group of Ph-negative Myeloproliferative Neoplasms (GEMFIN) using the Delphi method. Annals of hematology, 2016, Volume: 95, Issue:5 Topics: Bone Marrow Examination; Delphi Technique; Diagnosis, Differential; Disease Management; DNA Mutational Analysis; Humans; Hydroxyurea; Janus Kinase 2; Mutation, Missense; Platelet Count; Polycythemia Vera; Prognosis; Quinazolines; Receptors, Thrombopoietin; Risk Assessment; Surveys and Questionnaires; Thrombocythemia, Essential; Thrombophilia	2016
Influence of platelet and white blood cell counts on major thrombosis - analysis from a patient registry in essential thrombocythemia. European journal of haematology, 2016, Volume: 97, Issue:6 Topics: Aged; Blood Platelets; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Leukocyte Count; Male; Middle Aged; Platelet Aggregation Inhibitors; Prognosis; Proportional Hazards Models; Quinazolines; Registries; Risk Assessment; Thrombocythemia, Essential; Thrombosis	2016
Anagrelide and Mutational Status in Essential Thrombocythemia. BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy, 2016, Volume: 30, Issue:3 Topics: Adult; Calreticulin; Female; Humans; Janus Kinase 2; Male; Middle Aged; Mutation; Platelet Aggregation Inhibitors; Quinazolines; Receptors, Thrombopoietin; Retrospective Studies; Thrombocythemia, Essential; Treatment Outcome	2016
[Hematologic Malignancies/Pediatric Malignancies. II. Treatment of Essential Thrombocythemia--The Role of Anagrelide]. Gan to kagaku ryoho. Cancer & chemotherapy, 2016, Volume: 43, Issue:5 Topics: Child; Hematologic Neoplasms; Humans; Platelet Aggregation Inhibitors; Prognosis; Quinazolines; Thrombocythemia, Essential	2016
Acute pancreatitis as a side effect of anagrelide hydrochloride hydrate: a case report. Annals of hematology, 2016, Volume: 95, Issue:11 Topics: Abdominal Pain; Acute Disease; Aged; Aspirin; Drug Substitution; Female; Humans; Hydroxyurea; Janus Kinase 2; Mutation; Pancreatitis; Phosphodiesterase Inhibitors; Quinazolines; Thrombocythemia, Essential	2016
Anagrelide reduces thrombotic risk in essential thrombocythaemia vs. hydroxyurea plus aspirin. European journal of haematology, 2017, Volume: 98, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Aspirin; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Hungary; Hydroxyurea; Male; Middle Aged; Platelet Aggregation Inhibitors; Quinazolines; Risk; Thrombocythemia, Essential; Thrombosis	2017
Observational retrospective study of vascular modulator changes during treatment in essential thrombocythemia. Translational research : the journal of laboratory and clinical medicine, 2017, Volume: 184 Topics: Adrenomedullin; Aged; Aspirin; Blood Platelets; Case-Control Studies; Cell-Derived Microparticles; Endothelin-1; Endothelium, Vascular; Female; Humans; Hydroxyurea; Male; Middle Aged; Nitric Oxide; Quinazolines; Retrospective Studies; Thrombocythemia, Essential	2017
Hydroxyurea and anagrelide combination therapy in patients with chronic myeloproliferative diseases resistant or intolerant to monotherapy. Acta haematologica, 2008, Volume: 120, Issue:4 Topics: Adult; Aged; Aged, 80 and over; Drug Resistance; Drug Therapy, Combination; Female; Humans; Hydroxyurea; Male; Middle Aged; Polycythemia Vera; Quinazolines; Thrombocythemia, Essential	2008
Anagrelide for the treatment of essential thrombocythemia: a survey among European hematologists/oncologists. Hematology (Amsterdam, Netherlands), 2009, Volume: 14, Issue:1 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Data Collection; Europe; Humans; Janus Kinase 2; Middle Aged; Platelet Aggregation Inhibitors; Practice Patterns, Physicians'; Quinazolines; Thrombocythemia, Essential; Young Adult	2009
Involvement of mast cells by the malignant process in patients with Philadelphia chromosome negative myeloproliferative neoplasms. Leukemia, 2009, Volume: 23, Issue:9 Topics: Antigens, CD34; Cells, Cultured; Erlotinib Hydrochloride; Humans; Janus Kinase 2; Mast Cells; Mutation; Polycythemia Vera; Primary Myelofibrosis; Quinazolines; Receptors, Thrombopoietin; Thrombocythemia, Essential	2009
[Retrospective analysis of the efficacy and tolerability of anagrelide in patients with essential thrombocytemia: Spanish registry of essential thrombocytemia]. Medicina clinica, 2009, Jun-20, Volume: 133, Issue:3 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Female; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Quinazolines; Retrospective Studies; Thrombocythemia, Essential	2009
Management of refractory essential thrombocythemia with anagrelide in a patient undergoing hemodialysis. Clinical therapeutics, 2009, Volume: 31, Issue:11 Topics: Aged; Aspirin; Blood Cell Count; Blood Chemical Analysis; Blood Transfusion; Drug Resistance; Erythropoietin; Fatal Outcome; Female; Humans; Hydroxyurea; Jehovah's Witnesses; Kidney Failure, Chronic; Kidney Function Tests; Platelet Aggregation Inhibitors; Platelet Count; Quinazolines; Recombinant Proteins; Renal Dialysis; Thrombocythemia, Essential	2009
Anagrelide for the treatment of thrombocythaemia in daily clinical practice: a post-marketing observational survey on efficacy and safety performed in Germany. Onkologie, 2010, Volume: 33, Issue:1-2 Topics: Adult; Aged; Aged, 80 and over; Female; Humans; Ischemic Attack, Transient; Male; Middle Aged; Platelet Aggregation Inhibitors; Platelet Count; Product Surveillance, Postmarketing; Quinazolines; Thrombocythemia, Essential; Thrombosis; Young Adult	2010
[Essential thrombocythaemia and other myeloproliferative disorders with thrombocythaemia treated with Thromboreductin. A report from the database of register for the 1st quarter of 2010]. Vnitrni lekarstvi, 2010, Volume: 56, Issue:6 Topics: Adult; Aged; Female; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Platelet Count; Polycythemia Vera; Primary Myelofibrosis; Quinazolines; Thrombocythemia, Essential	2010
Low impact of cardiovascular adverse events on anagrelide treatment discontinuation in a cohort of 232 patients with essential thrombocythemia. Leukemia research, 2011, Volume: 35, Issue:12 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Cardiovascular Diseases; Child; Cohort Studies; Drug-Related Side Effects and Adverse Reactions; Female; Follow-Up Studies; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Quinazolines; Retrospective Studies; Thrombocythemia, Essential; Withholding Treatment; Young Adult	2011
Anagrelide and cardiovascular events. Much ado about nothing? Leukemia research, 2011, Volume: 35, Issue:12 Topics: Cardiovascular Diseases; Female; Humans; Male; Quinazolines; Thrombocythemia, Essential; Withholding Treatment	2011
Inverted takotsubo cardiomyopathy in a patient with essential thrombocythemia exposed to anagrelide and phentermine. International journal of cardiology, 2012, Oct-04, Volume: 160, Issue:2 Topics: Adult; Appetite Depressants; Female; Humans; Phentermine; Platelet Aggregation Inhibitors; Quinazolines; Takotsubo Cardiomyopathy; Thrombocythemia, Essential	2012
Impaired apoptosis of megakaryocytes and bone marrow mononuclear cells in essential thrombocythemia: correlation with JAK2V617F mutational status and cytoreductive therapy. Medical oncology (Northwood, London, England), 2012, Volume: 29, Issue:4 Topics: Adult; Aged; Aged, 80 and over; Apoptosis; Bone Marrow Cells; Female; Humans; Hydroxyurea; Janus Kinase 2; Male; Megakaryocytes; Middle Aged; Mutation; Proto-Oncogene Proteins c-bcl-2; Quinazolines; Thrombocythemia, Essential	2012
Clinical evaluation of the European LeukemiaNet response criteria in patients with essential thrombocythemia treated with anagrelide. Annals of hematology, 2013, Volume: 92, Issue:6 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Biomarkers; Disease-Free Survival; Female; Follow-Up Studies; Humans; Hydroxyurea; Interferons; International Agencies; Kaplan-Meier Estimate; Leukocyte Count; Male; Middle Aged; Organ Size; Platelet Aggregation Inhibitors; Platelet Count; Prognosis; Quinazolines; Remission Induction; Retrospective Studies; Spain; Spleen; Survival Analysis; Thrombocythemia, Essential; Treatment Outcome; Young Adult	2013
[Treatment of essential thrombocythemia with anagrelide: a ten-year experience]. Medicina, 2002, Volume: 62, Issue:3 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Child; Female; Follow-Up Studies; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Platelet Count; Quinazolines; Thrombocythemia, Essential; Treatment Outcome	2002
Efficacy and safety of long-term use of hydroxyurea in young patients with essential thrombocythemia and a high risk of thrombosis. Blood, 2003, May-01, Volume: 101, Issue:9 Topics: Adolescent; Adult; Anemia; Cohort Studies; Follow-Up Studies; Hemorrhage; Humans; Hydroxyurea; Incidence; Middle Aged; Quinazolines; Risk; Thrombocythemia, Essential; Thrombophilia; Thrombosis	2003
Associated thrombophilic defects in essential thrombocythaemia: their relationship with clinical manifestations. Thrombosis research, 2003, Volume: 112, Issue:3 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amino Acid Substitution; Antithrombin III; Child; Female; Humans; Hydroxyurea; Male; Middle Aged; Platelet Aggregation Inhibitors; Protein C; Prothrombin; Quinazolines; Reference Values; Thrombocythemia, Essential; Thrombophilia	2003
Essential thrombocythaemia in children: is a treatment needed? Expert opinion on pharmacotherapy, 2004, Volume: 5, Issue:5 Topics: Adult; Aspirin; Child; Clinical Trials, Phase II as Topic; Humans; Interferon-alpha; Quinazolines; Thrombocythemia, Essential	2004
Anagrelide therapy in pregnancy: report of a case of essential thrombocythemia. Annals of hematology, 2004, Volume: 83, Issue:11 Topics: Adult; Female; Humans; Pregnancy; Pregnancy Complications, Hematologic; Quinazolines; Thrombocythemia, Essential	2004
Anagrelide-induced visual hallucinations in a patient with essential thrombocythemia. European journal of haematology, 2004, Volume: 73, Issue:3 Topics: Aged; Female; Hallucinations; Humans; Platelet Aggregation Inhibitors; Quinazolines; Thrombocythemia, Essential	2004
Effects of anagrelide on platelet factor 4 and vascular endothelial growth factor levels in patients with essential thrombocythemia. British journal of haematology, 2004, Volume: 126, Issue:6 Topics: Adult; Blood Platelets; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Platelet Factor 4; Quinazolines; Thrombocythemia, Essential; Vascular Endothelial Growth Factor A	2004
A long-term study of young patients with essential thrombocythemia treated with anagrelide. Haematologica, 2004, Volume: 89, Issue:11 Topics: Adult; Anemia; Female; Hemoglobins; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Quinazolines; Stomach Diseases; Tachycardia; Thrombocythemia, Essential; Time Factors	2004
Anagrelide-associated cardiomyopathy in polycythemia vera and essential thrombocythemia. Haematologica, 2004, Volume: 89, Issue:11 Topics: Cardiomyopathies; Female; Humans; Platelet Aggregation Inhibitors; Polycythemia Vera; Quinazolines; Thrombocythemia, Essential	2004
PDGF-A, PDGF-B, TGFbeta, and bFGF mRNA levels in patients with essential thrombocythemia treated with anagrelide. American journal of hematology, 2005, Volume: 78, Issue:2 Topics: Blood Platelets; Fibroblast Growth Factor 2; Growth Substances; Humans; Middle Aged; Platelet-Derived Growth Factor; Proto-Oncogene Proteins c-sis; Quinazolines; RNA, Messenger; Thrombocythemia, Essential; Transforming Growth Factor beta	2005
[Anagrelide in the treatment of thrombocythemia essential (ET)]. Polskie Archiwum Medycyny Wewnetrznej, 2004, Volume: 112, Issue:6 Topics: Adult; Aged; Blood Platelets; Dose-Response Relationship, Drug; Female; Fibrinolytic Agents; Follow-Up Studies; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Platelet Count; Poland; Quinazolines; Retrospective Studies; Thrombocythemia, Essential; Time Factors; Treatment Outcome	2004
When and how to treat essential thrombocythemia. The New England journal of medicine, 2005, Jul-07, Volume: 353, Issue:1 Topics: Antineoplastic Agents; Aspirin; Drug Therapy, Combination; Hemorrhage; Humans; Hydroxyurea; Leukemia, Myeloid, Acute; Platelet Aggregation Inhibitors; Primary Myelofibrosis; Quinazolines; Risk Factors; Thrombocythemia, Essential; Thrombosis	2005
Moyamoya syndrome in an adolescent with essential thrombocythemia: successful intracranial carotid stent placement. Stroke, 2005, Volume: 36, Issue:8 Topics: Adolescent; Angiography; Brain; Cerebral Revascularization; Cerebrovascular Circulation; Female; Humans; Moyamoya Disease; Quinazolines; Regional Blood Flow; Stents; Thrombocythemia, Essential; Time Factors; Treatment Outcome; Ultrasonography, Doppler	2005
High-output heart failure associated with anagrelide therapy for essential thrombocytosis. Annals of internal medicine, 2005, Aug-16, Volume: 143, Issue:4 Topics: Adult; Cardiac Output; Heart Failure; Humans; Male; Platelet Aggregation Inhibitors; Quinazolines; Thrombocythemia, Essential	2005
Treatment of symptomatic patients with essential thrombocythemia: effectiveness of anagrelide. American journal of hematology, 2005, Volume: 80, Issue:1 Topics: Adult; Aged; Blood Coagulation; Female; Humans; Lipoproteins; Male; Middle Aged; Platelet Aggregation Inhibitors; Platelet Count; Platelet Factor 4; Quinazolines; Thrombocythemia, Essential; Thrombosis	2005
'Double hit' from streptococcal pneumonia and hypersensitivity pneumonitis associated with anagrelide. Clinical and laboratory haematology, 2006, Volume: 28, Issue:1 Topics: Adrenal Cortex Hormones; Alveolitis, Extrinsic Allergic; Drug Hypersensitivity; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Pneumonia, Pneumococcal; Quinazolines; Thrombocythemia, Essential	2006
Bilateral adrenal hemorrhage associated with essential thrombocytosis. American journal of hematology, 2006, Volume: 81, Issue:2 Topics: Adrenal Insufficiency; Aged; Hemorrhage; Humans; Magnetic Resonance Imaging; Male; Quinazolines; Thrombocythemia, Essential	2006
Emergence of chronic myelogenous leukemia in a patient with primary thrombocythemia and absence of BCR/ABL rearrangement. Cancer genetics and cytogenetics, 2006, Volume: 167, Issue:1 Topics: Aged; Antineoplastic Agents; Benzamides; Blood Platelets; Bone Marrow Cells; Cells, Cultured; Chromosomes, Human, Pair 22; Chromosomes, Human, Pair 9; Chronic Disease; Dose-Response Relationship, Drug; Female; Fibrinolytic Agents; Fusion Proteins, bcr-abl; Humans; Hydroxyurea; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Karyotyping; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukocytes; Piperazines; Pyrimidines; Quinazolines; Thrombocythemia, Essential; Time Factors; Translocation, Genetic; Treatment Outcome	2006
Anagrelide: new drug. Essential thrombocythaemia: further evaluation needed for this last-resort treatment. Prescrire international, 2006, Volume: 15, Issue:83 Topics: Clinical Trials as Topic; Cost-Benefit Analysis; Drug Approval; Drugs, Investigational; Europe; Humans; Hydroxyurea; Platelet Aggregation Inhibitors; Quinazolines; Thrombocythemia, Essential; Treatment Outcome; Vasodilator Agents	2006
[Anagrelide in the treatment of essential thrombocythemia (ET) and other myeloproliferative disorders with thrombocythemia based on data from patient register in the CR]. Vnitrni lekarstvi, 2006, Volume: 52, Issue:5 Topics: Humans; Myeloproliferative Disorders; Platelet Aggregation Inhibitors; Quinazolines; Thrombocythemia, Essential; Thrombocytosis	2006
Effects of anagrelide on megakaryopoiesis and platelet production. Seminars in thrombosis and hemostasis, 2006, Volume: 32, Issue:4 Pt 2 Topics: Animals; Antineoplastic Agents; Apoptosis; Bone Marrow; Cell Differentiation; Drug Evaluation; Humans; Hydroxyurea; Megakaryocytes; Mutagenesis; Platelet Aggregation Inhibitors; Ploidies; Primary Myelofibrosis; Quinazolines; Thrombocythemia, Essential; Thrombopoiesis; World Health Organization	2006
Acute biphenotypic leukemia arising in a patient with essential thrombocythemia. American journal of hematology, 2006, Volume: 81, Issue:8 Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Chromosome Aberrations; Chromosomes, Human, Pair 20; Cytogenetic Analysis; Female; Follow-Up Studies; Humans; Hydroxyurea; Leukemia; Middle Aged; Quinazolines; Remission Induction; Thrombocythemia, Essential; Treatment Outcome	2006
Long-term use of anagrelide in the treatment of children with essential thrombocythemia. European journal of haematology, 2006, Volume: 77, Issue:4 Topics: Adolescent; Child; Female; Humans; Male; Platelet Aggregation Inhibitors; Quinazolines; Thrombocythemia, Essential	2006
Coronary artery intervention after cytostatics treatment in unstable angina patient with essential thrombocythemia. A case report and literature review. The Korean journal of internal medicine, 2006, Volume: 21, Issue:2 Topics: Angina, Unstable; Angioplasty, Balloon, Coronary; Humans; Hydroxyurea; Male; Middle Aged; Quinazolines; Stents; Thrombocythemia, Essential	2006
Acute coronary syndromes and Anagrelide. International journal of cardiology, 2007, Apr-12, Volume: 117, Issue:1 Topics: Angina Pectoris, Variant; Female; Humans; Middle Aged; Platelet Aggregation Inhibitors; Quinazolines; Thrombocythemia, Essential; Treatment Outcome	2007
Essential thrombocythaemia treatment options: addressing patient-specific needs. European journal of haematology. Supplementum, 2007, Issue:68 Topics: Disease Management; Health Services Needs and Demand; Humans; Hydroxyurea; Interferon alpha-2; Interferon-alpha; Platelet Count; Polyethylene Glycols; Quinazolines; Recombinant Proteins; Risk Factors; Thrombocythemia, Essential	2007
Options in the management of essential thrombocythaemia. European journal of haematology. Supplementum, 2007, Issue:68 Topics: Age Factors; Disease Management; Humans; Hydroxyurea; Interferons; Platelet Count; Quinazolines; Risk Factors; Thrombocythemia, Essential	2007
Practical approach to treating essential thrombocythaemia: case studies. European journal of haematology. Supplementum, 2007, Issue:68 Topics: Adult; Aspirin; Disease Management; Female; Humans; Hydroxyurea; Interferon-alpha; Leg Ulcer; Male; Middle Aged; Pipobroman; Platelet Count; Pregnancy; Pregnancy Complications, Hematologic; Quinazolines; Thrombocythemia, Essential; Warfarin	2007
Successful rechallenge with anagrelide in a patient with anagrelide-associated cardiomyopathy. Annals of hematology, 2008, Volume: 87, Issue:8 Topics: Cardiomyopathy, Dilated; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Quinazolines; Thrombocythemia, Essential	2008
Interferon-alpha in the treatment of essential thrombocythemia. Leukemia & lymphoma, 1996, Volume: 22 Suppl 1 Topics: Bone Marrow; Clinical Trials as Topic; Follow-Up Studies; Humans; Immunologic Factors; Interferon-alpha; Megakaryocytes; Middle Aged; Platelet Aggregation Inhibitors; Platelet Count; Quinazolines; Remission Induction; Thrombocythemia, Essential	1996
Anagrelide, a novel platelet lowering option in essential thrombocythaemia: treatment experience in 48 patients in Germany. European journal of haematology, 1998, Volume: 61, Issue:2 Topics: Administration, Oral; Adult; Aged; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Quinazolines; Risk Factors; Thrombocythemia, Essential; Treatment Outcome	1998
[Chronic myeloproliferative diseases]. Orvosi hetilap, 1998, Jul-26, Volume: 139, Issue:30 Topics: Chronic Disease; Female; Fibrinolytic Agents; Humans; Interferons; Leukemia, Myeloid; Male; Myeloproliferative Disorders; Polycythemia Vera; Primary Myelofibrosis; Quinazolines; Thrombocythemia, Essential	1998
Anagrelide-induced relapse of a hydroxyurea-induced leg ulcer in a patient with primary thrombocythemia. Mayo Clinic proceedings, 1998, Volume: 73, Issue:11 Topics: Aged; Antineoplastic Agents; Female; Fibrinolytic Agents; Humans; Hydroxyurea; Leg Ulcer; Platelet Aggregation Inhibitors; Quinazolines; Recurrence; Thrombocythemia, Essential	1998
[Anagrelide in control of myeloproliferative thrombocythemia: long-term experiences in 6 patients]. Schweizerische medizinische Wochenschrift, 1998, Nov-14, Volume: 128, Issue:46 Topics: Adult; Aged; Aged, 80 and over; Female; Follow-Up Studies; Humans; Male; Middle Aged; Myeloproliferative Disorders; Platelet Aggregation Inhibitors; Platelet Count; Quinazolines; Thrombocythemia, Essential; Thrombocytosis; Treatment Outcome	1998
Cost-effectiveness model of a phase II clinical trial of a new pharmaceutical for essential thrombocythemia: is it helpful to policy makers? Seminars in hematology, 1999, Volume: 36, Issue:1 Suppl 2 Topics: Clinical Trials, Phase II as Topic; Cost-Benefit Analysis; Humans; Models, Economic; Platelet Aggregation Inhibitors; Policy Making; Quinazolines; Thrombocythemia, Essential	1999
Studies of platelet volume, chemistry and function in patients with essential thrombocythaemia treated with Anagrelide. British journal of haematology, 1999, Volume: 104, Issue:4 Topics: Bleeding Time; Blood Platelets; Child; Humans; Middle Aged; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Count; Quinazolines; Thrombocythemia, Essential	1999
Long-term use of anagrelide in young patients with essential thrombocythemia. Blood, 2001, Feb-15, Volume: 97, Issue:4 Topics: Adolescent; Adult; Female; Hemorrhage; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Quinazolines; Remission Induction; Retrospective Studies; Thrombocythemia, Essential; Thrombosis; Treatment Outcome	2001
[Thromboxane B2 and platelet derived growth factor in essential thrombocythemia treated with anagrelide]. Medicina, 2000, Volume: 60, Issue:4 Topics: Adult; Aged; Female; Fibrinolytic Agents; Humans; Immunoenzyme Techniques; Male; Middle Aged; Platelet Count; Platelet-Derived Growth Factor; Quinazolines; Thrombocythemia, Essential; Thromboxane B2	2000
[Anagrelide in primary thrombocythemia]. Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke, 2001, May-10, Volume: 121, Issue:12 Topics: Adult; Female; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Prospective Studies; Quinazolines; Retrospective Studies; Thrombocythemia, Essential	2001
[How should patients with essential thrombocythemia be treated?]. [Rinsho ketsueki] The Japanese journal of clinical hematology, 2001, Volume: 42, Issue:6 Topics: Clinical Trials as Topic; Enzyme Inhibitors; Humans; Hydroxyurea; Leukemia; Platelet Aggregation Inhibitors; Quinazolines; Thrombocythemia, Essential	2001
Effects of anagrelide on in vivo megakaryocyte proliferation and maturation in essential thrombocythemia. Blood, 2002, Mar-01, Volume: 99, Issue:5 Topics: Blood Platelets; Bone Marrow Cells; Cell Differentiation; Cell Division; Cell Survival; Flow Cytometry; Hematopoiesis; Humans; Indium Radioisotopes; Megakaryocytes; Platelet Aggregation Inhibitors; Quinazolines; Thrombocythemia, Essential	2002
Essential thrombocythemia in young adults. Mayo Clinic proceedings, 1991, Volume: 66, Issue:2 Topics: Adolescent; Adult; Child; Epinephrine; Female; Follow-Up Studies; Humans; Male; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Count; Prognosis; Quinazolines; Retrospective Studies; Thrombocythemia, Essential; Thrombosis	1991
Essential thrombocythemia in a child: management with anagrelide. The American journal of pediatric hematology/oncology, 1991,Spring, Volume: 13, Issue:1 Topics: Aspirin; Child; Drug Therapy, Combination; Humans; Male; Platelet Aggregation Inhibitors; Platelet Count; Quinazolines; Thrombocythemia, Essential	1991
Anagrelide: a new drug for treating thrombocytosis. The New England journal of medicine, 1988, May-19, Volume: 318, Issue:20 Topics: Adult; Aged; Female; Hematopoietic Stem Cells; Humans; Male; Middle Aged; Myeloproliferative Disorders; Platelet Aggregation Inhibitors; Platelet Count; Polycythemia Vera; Quinazolines; Thrombocythemia, Essential; Thrombocytosis	1988